Hancock Jaffe Laboratories Inc Net debt/EBITDA
What is the Net debt/EBITDA of Hancock Jaffe Laboratories Inc?
The Net debt/EBITDA of Hancock Jaffe Laboratories Inc is 1.20
What is the definition of Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA of companies in the Health Care sector on NASDAQ compared to Hancock Jaffe Laboratories Inc
What does Hancock Jaffe Laboratories Inc do?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Companies with net debt/ebitda similar to Hancock Jaffe Laboratories Inc
- Gold Springs Resource has Net debt/EBITDA of 1.19
- ObsEva SA has Net debt/EBITDA of 1.19
- Kenmare Resources plc has Net debt/EBITDA of 1.19
- EEStor has Net debt/EBITDA of 1.20
- China Leasing has Net debt/EBITDA of 1.20
- Midland has Net debt/EBITDA of 1.20
- Hancock Jaffe Laboratories Inc has Net debt/EBITDA of 1.20
- Outset Medical has Net debt/EBITDA of 1.20
- Invesco has Net debt/EBITDA of 1.20
- Kits Eyecare has Net debt/EBITDA of 1.20
- Dare Bioscience Inc has Net debt/EBITDA of 1.20
- Sierra Madre Gold and Silver has Net debt/EBITDA of 1.21
- Greenfirst Forest Products Inc has Net debt/EBITDA of 1.21